25-03-17	Calendar Monday, March 17	FW
25-03-17	Abliva has today the last trading day on Nasdaq Stockholm before delisting	FW
25-03-07	Pharming Group Unit's Ownership of Abliva Tops 97% After Takeover Offer Extension	MT
25-03-03	Abliva is delisted from Nasdaq Stockholm with the last trading day on March 17	FW
25-02-26	Alexander Breidenbach Proposed As Board Chairman	RE
25-02-25	Abliva Applies to Delist From Nasdaq Stockholm	MT
25-02-25	Abliva applies for delisting from Nasdaq Stockholm	FW
25-02-24	Abliva AB(OM:ABLI) dropped from OMX Nordic Small Cap Index	CI
25-02-24	Abliva AB(OM:ABLI) dropped from OMX Nordic All-Share Index	CI
25-02-21	Abliva reports small changes in earnings	FW
25-02-21	Abliva Proposes No Dividend For 2024	RE
25-02-21	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-02-21	Pharming controls 92.7 percent of Abliva - intends to call for compulsory acquisition	FW

More news

Analysts' recommendations: Abliva AB

24-12-17	Affärsvärlden sees many indications that the takeover bid for Abliva will go through	FW
24-12-16	Abliva bid has attractive premium, high probability of success - Penser	FW
24-07-29	Abliva well positioned after positive results - Penser	FW
24-05-27	Penser: Abliva's Q1 in line with expectations - focus on upcoming interim analysis	FW
24-02-27	Penser: No surprises in Q4 from Abliva - costs expected to continue to rise	FW

More recommendations

Press Releases: Abliva AB

25-03-17	BioStock: Last trading day for Abliva - the company leaves Nasdaq Stockholm	AQ
25-03-03	Delisting of the shares of Abliva: last day of trading 17 March 2025	AQ
25-02-26	Notice of Extraordinary General Meeting in Abliva AB (publ)	AQ
25-02-25	Abliva applies for delisting and will convene an extraordinary general meeting	AQ
25-02-21	Abliva AB Year-End Report January – December 2024	AQ

More press releases

Quotes and Performance

1 day

+23.92%

More quotes

Course Extremes

3 years	0		0.04
5 years	0		0.08
10 years	0		0.73

More quotes

Managers and Directors: Abliva AB

Manager	Title	Age	Since
Catharina Jz Johansson DFI	Director of Finance/CFO	59	2014-01-09
Dag Nesse CTO	Chief Tech/Sci/R&D Officer	60	2023-01-31
Magnus Hansson CTO	Chief Tech/Sci/R&D Officer	50	2015-12-31

Director	Title	Age	Since
David Laskow-Pooley CHM	Chairman	72	2017-11-05
Jan Birger Fredrik Toernell BRD	Director/Board Member	66	2017-04-26
David Bejker BRD	Director/Board Member	51	2017-04-26

More insiders

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABLIVA AB	+23.92%	-.--%	-	-	76M
ARGENX SE	+2.87%	+1.58%	+68.97%	+122.28%	55.19B
WUXI APPTEC CO., LTD.	+4.00%	+7.14%	+63.67%	+68.77%	45.75B
BIONTECH SE	-0.77%	-0.39%	-15.34%	-16.07%	22.98B
INSMED INCORPORATED	+2.93%	+0.77%	-3.97%	+376.58%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	-0.26%	-1.09%	+27.55%	-18.57%	16.26B
GENMAB A/S	+1.16%	+2.25%	+20.23%	-35.78%	15.42B
EXELIXIS, INC.	-1.08%	-3.35%	+27.20%	+170.12%	13.05B
PHARMAESSENTIA CORPORATION	+3.30%	+15.38%	+133.24%	+273.89%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-5.63%	-5.49%	+21.79%	-	12.37B
Average	+3.04%	+3.15%	+38.15%	+117.65%	23.8B
Weighted average by Cap.	+1.67%	+2.66%	+43.54%	+109.58%

See all sector performances

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

-40%: Exceptional extension

SEIZE THE OFFER!